ES2186797T3 - Metodo para detectar, identificar, aislar y marcar selectivamente, y direccionar linfocitos th1 por medio de la proteina lag-3. - Google Patents
Metodo para detectar, identificar, aislar y marcar selectivamente, y direccionar linfocitos th1 por medio de la proteina lag-3.Info
- Publication number
- ES2186797T3 ES2186797T3 ES96926748T ES96926748T ES2186797T3 ES 2186797 T3 ES2186797 T3 ES 2186797T3 ES 96926748 T ES96926748 T ES 96926748T ES 96926748 T ES96926748 T ES 96926748T ES 2186797 T3 ES2186797 T3 ES 2186797T3
- Authority
- ES
- Spain
- Prior art keywords
- lag
- lymphocytes
- cells
- methods
- directing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000004698 lymphocyte Anatomy 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 102000017578 LAG3 Human genes 0.000 title 1
- 101150030213 Lag3 gene Proteins 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 108090000978 Interleukin-4 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002596 correlated effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
Abstract
EL GEN DE ACTIVACION DE LINFOCITOS (LAG-3) ES UN MIEMBRO DE LA SUPERFAMILIA DE LAS INMUNOGLOBULINAS QUE ES TRANSCRITO SELECTIVAMENTE EN LAS CELULAS T Y NK HUMANAS ACTIVADAS. SU EXPRESION EN LA SUPERFICIE DE LAG-3 SE HA CORRELACIONADO CON LA PRODUCCION DE IFN- GA} PERO NO DE IL-4, EN CELULAS T ESTIMULADAS POR EL ANTIGENO Y ESTUVO REGULADA POSITIVAMENTE POR IL-12 Y ESTA PREFERENTEMENTE ASOCIADA CON CELULAS T CD4+ PRODUCTORAS DE CITOCINAS DE TIPO TH1. LA PRESENCIA DE LAG-3 EN LA SUPERFICIE DE LINFOCITOS TH1 SE USA COMO MARCADOR PARA DETECTAR E IDENTIFICAR A LOS LINFOCITOS TH1 Y DIFERENCIARLOS DE LOS LINFOCITOS TH2. LOS ANTICUERPOS MONOCLONALES PARA LAG-3 SE USAN EN DIVERSOS METODOS PARA DETECTAR Y AISLAR CELULAS TH1 ASI COMO TAMBIEN EN METODOS PARA DIAGNOSTICAR ENFERMEDADES MEDIADAS POR CELULAS TH1. LA INVENCION ACTUAL TAMBIEN SE REFIERE A METODOS PARA TRATAR ENFERMEDADES INFECCIOSAS, CANCER Y TRASTORNOS QUE SE ACOMPAÑAN DE DESEQUILIBRIO DE LA RELACI N TH1/TH2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US136795P | 1995-07-21 | 1995-07-21 | |
US268395P | 1995-09-21 | 1995-09-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2186797T3 true ES2186797T3 (es) | 2003-05-16 |
Family
ID=26668940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES96926748T Expired - Lifetime ES2186797T3 (es) | 1995-07-21 | 1996-07-19 | Metodo para detectar, identificar, aislar y marcar selectivamente, y direccionar linfocitos th1 por medio de la proteina lag-3. |
Country Status (12)
Country | Link |
---|---|
US (1) | US6197524B1 (es) |
EP (1) | EP0843557B1 (es) |
JP (2) | JP2000508226A (es) |
AT (1) | ATE227586T1 (es) |
AU (1) | AU701375B2 (es) |
CA (1) | CA2227334A1 (es) |
DE (1) | DE69624824T2 (es) |
DK (1) | DK0843557T3 (es) |
ES (1) | ES2186797T3 (es) |
IL (1) | IL122832A (es) |
PT (1) | PT843557E (es) |
WO (1) | WO1997003695A1 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1373099A (en) * | 1997-11-13 | 1999-06-07 | Napolitano, Monica | Th2 cell depletion; compositions; methods |
ATE519779T1 (de) * | 2001-09-19 | 2011-08-15 | Roussy Inst Gustave | An das glu-pro motiv-bindende proteine und peptide, diese enthaltende therapeutische zusammensetzungen und deren anwendungen |
KR100615389B1 (ko) * | 2002-08-23 | 2006-08-25 | (주)헬릭서 | 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품 |
CA2517287C (en) * | 2003-02-28 | 2022-12-13 | The Johns Hopkins University | Regulation of t cells by lag-3 (cd223) |
EP1987839A1 (en) * | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
WO2012003479A2 (en) | 2010-07-01 | 2012-01-05 | Regenerative Research Foundation | Methods for culturing undifferentiated cells using sustained release compositions |
AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
ME03796B (me) | 2013-03-15 | 2021-04-20 | Glaxosmithkline Ip Dev Ltd | Anti-lag-3 vezujući proteini |
SG11201601763SA (en) | 2013-09-20 | 2016-04-28 | Bristol Myers Squibb Co | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
US20150231077A1 (en) | 2014-02-17 | 2015-08-20 | The Cleveland Clinic Foundation | Amine passivated nanoparticles for cancer treatment and imaging |
KR102442436B1 (ko) * | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
MA47849A (fr) | 2014-05-28 | 2020-01-29 | Agenus Inc | Anticorps anti-gitr et leurs procédés d'utilisation |
JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
TWI773646B (zh) * | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
JP7074341B2 (ja) | 2015-09-02 | 2022-05-24 | イムテップ エス.アー.エス. | 抗lag-3抗体 |
TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗lag3抗體及其用途 |
US11447557B2 (en) | 2015-12-02 | 2022-09-20 | Agenus Inc. | Antibodies and methods of use thereof |
BR112018012352A2 (pt) | 2015-12-16 | 2018-12-11 | Merck Sharp & Dohme Corp. | anticorpos anti-lag3 e fragmentos de ligação ao antígeno |
MA46529A (fr) | 2016-10-11 | 2019-08-21 | Agenus Inc | Anticorps anti-lag-3 et leurs procédés d'utilisation |
MA46814B2 (fr) | 2017-02-10 | 2022-09-30 | Regeneron Pharma | Anticorps anti-lag3 radiomarqués pour imagerie immuno-pet |
AU2018275209A1 (en) | 2017-05-30 | 2019-10-17 | Bristol-Myers Squibb Company | Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody |
LT3631454T (lt) | 2017-05-30 | 2023-11-27 | Bristol-Myers Squibb Company | Lag-3 atžvilgiu teigiamų navikų gydymas |
WO2020232019A1 (en) | 2019-05-13 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2656800B1 (fr) * | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
CN1110557C (zh) * | 1994-05-06 | 2003-06-04 | 古斯达威罗斯研究所 | Lag-3蛋白的可溶性多肽组分;生产方法、治疗组合物、抗独特型抗体 |
-
1996
- 1996-07-19 DE DE69624824T patent/DE69624824T2/de not_active Expired - Lifetime
- 1996-07-19 AU AU66784/96A patent/AU701375B2/en not_active Expired
- 1996-07-19 EP EP96926748A patent/EP0843557B1/en not_active Expired - Lifetime
- 1996-07-19 JP JP9506911A patent/JP2000508226A/ja active Pending
- 1996-07-19 PT PT96926748T patent/PT843557E/pt unknown
- 1996-07-19 CA CA002227334A patent/CA2227334A1/en not_active Abandoned
- 1996-07-19 US US08/983,576 patent/US6197524B1/en not_active Expired - Lifetime
- 1996-07-19 IL IL122832A patent/IL122832A/en not_active IP Right Cessation
- 1996-07-19 DK DK96926748T patent/DK0843557T3/da active
- 1996-07-19 AT AT96926748T patent/ATE227586T1/de active
- 1996-07-19 ES ES96926748T patent/ES2186797T3/es not_active Expired - Lifetime
- 1996-07-19 WO PCT/US1996/011994 patent/WO1997003695A1/en active IP Right Grant
-
2007
- 2007-11-07 JP JP2007289509A patent/JP2008150362A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU6678496A (en) | 1997-02-18 |
DK0843557T3 (da) | 2003-03-10 |
JP2008150362A (ja) | 2008-07-03 |
PT843557E (pt) | 2003-03-31 |
US6197524B1 (en) | 2001-03-06 |
EP0843557A1 (en) | 1998-05-27 |
ATE227586T1 (de) | 2002-11-15 |
DE69624824T2 (de) | 2003-09-11 |
IL122832A0 (en) | 1998-08-16 |
CA2227334A1 (en) | 1997-02-06 |
WO1997003695A1 (en) | 1997-02-06 |
DE69624824D1 (de) | 2002-12-19 |
EP0843557B1 (en) | 2002-11-13 |
EP0843557A4 (en) | 1999-04-14 |
AU701375B2 (en) | 1999-01-28 |
JP2000508226A (ja) | 2000-07-04 |
IL122832A (en) | 2006-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2186797T3 (es) | Metodo para detectar, identificar, aislar y marcar selectivamente, y direccionar linfocitos th1 por medio de la proteina lag-3. | |
Das et al. | Activity-induced convergence of APP and BACE-1 in acidic microdomains via an endocytosis-dependent pathway | |
CY1121645T1 (el) | Διαγνωση και θεραπεια των προκαλουμενων με αντισωμα φλεγμονωδων αυτοανοσων διαταραχων | |
ATE264717T1 (de) | Mikrofluidisches system und verfahren zu dessen betrieb | |
Rodríguez-Gómez et al. | Expression of T-bet, eomesodermin, and GATA-3 correlates with distinct phenotypes and functional properties in porcine γδ T cells | |
DK0943097T3 (da) | Fremgangsmåde til at påvise IgE | |
ES2121078T3 (es) | Clonacion y expresion de anticuerpos monoclonales humanizados contra interleuquina-4 humana. | |
DE69910362D1 (de) | Anwendung der mesenchymalen stammzellen als immunsuppressiva | |
ES2123475T1 (es) | Metodo y aparato para la integracion de un sistema automatizado a un laboratorio. | |
BRPI0513135A (pt) | bibliotecas de polinucleotìdeos, método de produção das mesmas, método de identificação de um polinucleotìdeo, região de ligação, meio adequado para uso em um, dispositivo eletrÈnico e dispositivo | |
DE69626683T2 (de) | Verfahren zur feststellung von antipolymerantikörper und diagnosetestsatz zur feststellung von siliconabhängigen krankheiten | |
CY1110144T1 (el) | Αντισωματα για την ταυτοποιηση και/ή την απομονωση τουλαχιστον ενος κυτταρικου πληθυσμου ο οποιος επιλεγεται απο την ομαδα την περιλαμβανουσα αιμοποιητικα βλαστοκυτταρα, νευρικα βλαστοκυτταρα, νευρικα αρχεγονα κυτταρα, μεσεγχυματικα βλαστοκυτταρα και μεσεγχυματικα αρχεγονα κυτταρα | |
Lopes et al. | Tissue-specific transcriptional profiles and heterogeneity of natural killer cells and group 1 innate lymphoid cells | |
DE60318987D1 (de) | Verfahren zur diagnose von juvenilen idiopathischen skoliosen und verwandten erkrankungen | |
ES2130672T3 (es) | Nuevos peptidos derivados de un antigeno y destinados para la inmunoterapia de las enfermedades autoinmunes. | |
ES2172287T4 (es) | Metodos de deteccion y tratamiento de individuos con celulas anormales que expresan los antigenos peptidicos hla-a2/tirosinasa. | |
Hansen et al. | Cutaneous T-cell lymphoma lesional epidermal cells activate autologous CD4+ T lymphocytes: involvement of both CD1+ OKM5+ and CD1+ OKM5− antigen-presenting cells | |
DK62887A (da) | Apparat til sortering med indbyggede fordelings- og udskilningsindretninger | |
DK0751780T3 (da) | Fremgangsmåder til isolering af CD1-fremviste antigener, vacciner, som omfatter CD1-fremviste antigener, og cellelinier til anvendelse i nævnte fremgangsmåder | |
ES2178677T3 (es) | Metodo para identificar compuestos, util para tratar enfermedades autoinmunes. | |
Renard et al. | The CD8β polypeptide is required for the recognition of an altered peptide ligand as an agonist | |
Hong | Update on the immunodeficiency diseases | |
Cardoso et al. | Impaired lymphocyte profile in schistosomiasis patients with periportal fibrosis | |
ATE192236T1 (de) | Menschliche phospholipase aktivierender proteinteil | |
Dulphy et al. | NKG2D ligands expression and NKG2D-mediated NK activity in Sezary patients |